Vaginal films for drug delivery

Journal of Pharmaceutical Sciences

Volumn 102, Issue 7, 2013, Pages 2069-2081

  Machado, Rita M ^a   Palmeira De Oliveira, Ana ^a   Martinez De Oliveira, José ^a,b   Palmeira De Oliveira, Rita ^a,b  

^a UNIVERSITY OF BEIRA INTERIOR   (Portugal)

^b Hospital Centre of Cova da Beira   (Portugal)

Author keywords

Bioadhesion; Contraceptive; Controlled release; Formulation; Mechanical properties; Microbicide; Mucosal drug delivery; Polymeric drug delivery systems; Vaginal dosage forms; Vaginal film

Indexed keywords

BENZALKONIUM CHLORIDE; DAPIVIRINE; IQP 0528; ITRACONAZOLE; NONOXINOL 9; UNCLASSIFIED DRUG;

DRUG DELIVERY DEVICE; DRUG FORMULATION; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; FIRST PASS EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTRAVAGINAL DRUG ADMINISTRATION; NONHUMAN; PATENT; REVIEW; VAGINAL FILM;

EID: 84879005008     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23577     Document Type: Review

References (58)

1. Acartürk F. 2009. Mucoadhesive vaginal drug delivery systems. Recent Pat Drug Deliv Formul 3(3):193-205.
2. Alexander NJ, Baker E, Kaptein M, Karck U, Miller L, Zampaglione E. 2004. Why consider vaginal drug administration? Fertil Steril 82(1):1-12.
3. Hussain A, Ahsan F. 2005. The vagina as a route for systemic drug delivery. J Control Release 103(2):301-313.
4. Ndesendo VM, Pillay V, Choonara YE, Buchmann E, Bayever DN, Meyer LC. 2008. A review of current intravaginal drug delivery approaches employed for the prophylaxis of HIV/AIDS and prevention of sexually transmitted infections. AAPS PharmSciTech 9(2):505-520.
5. Vermani K, Garg S. 2000. The scope and potential of vaginal drug delivery. Pharm Sci Technol Today 3(10):359-364.
6. Baloglu E, Senyigit ZA, Karavana SY, Bernkop-Schnurch A. 2009. Strategies to prolong the intravaginal residence time of drug delivery systems. J Pharm Pharm Sci 12(3):312-336.
7. Harwood B, Mishell DR, Jr. 2001. Contraceptive vaginal rings. Semin Reprod Med 19(4):381-390.
8. Trifonova RT, Pasicznyk JM, Fichorova RN. 2006. Biocompatibility of solid-dosage forms of anti-human immunodeficiency virus type 1 microbicides with the human cervicovaginal mucosa modeled ex vivo. Antimicrob Agents Chemother 50(12):4005-4010.
9. Harwood B, Meyn LA, Ballagh SA, Raymond EG, Archer DF, Creinin MD. 2008. Cervicovaginal colposcopic lesions associated with 5 nonoxynol-9 vaginal spermicide formulations. Am J Obstet Gynecol 198(1):32. e31-37.
10. Akil A, Parniak MA, Dezzuitti CS, Moncla BJ, Cost MR, Li M, Rohan LC. 2011. Development and characterization of a vaginal film containing dapivirine, a non- nucleoside reverse transcriptase inhibitor (NNRTI), for prevention of HIV-1 sexual transmission. Drug Deliv Transl Res 1(3):209-222.
11. Barnhart KT, Stolpen A, Pretorius ES, Malamud D. 2001. Distribution of a spermicide containing nonoxynol-9 in the vaginal canal and the upper female reproductive tract. Hum Reprod 16(6):1151-1154.
12. Gali Y, Delezay O, Brouwers J, Addad N, Augustijns P, Bourlet T, Hamzeh-Cognasse H, Arien KK, Pozzetto B, Vanham G. 2010. In vitro evaluation of viability, integrity, and inflammation in genital epithelia upon exposure to pharmaceutical excipients and candidate microbicides. Antimicrob Agents Chemother 54(12):5105-5114.
13. Gupta SK. 2011. Microbicides: A new hope for HIV prevention. Indian J Med Res 134(6):939-949.
14. Whaley KJ, Hanes J, Shattock R, Cone RA, Friend DR. 2010. Novel approaches to vaginal delivery and safety of microbicides: Biopharmaceuticals, nanoparticles, and vaccines. Antiviral Res 88 Suppl 1:S55-S66.
15. Rohan LC, Sassi AB. 2009. Vaginal drug delivery systems for HIV prevention. AAPS J 11(1):78-87.
16. Ham AS, Rohan LC, Boczar A, Yang L, KWB, Buckheit RW, Jr. 2012. Vaginal film drug delivery of the pyrimidinedione IQP-0528 for the prevention of HIV infection. Pharm Res 29(7):1897-1907.
17. Van De Graff K. 2001. Human anatomy. 6th ed. Europe: McGraw-Hill.
18. Pendergrass PB, Reeves CA, Belovicz MW, Molter DJ, White JH. 1996. The shape and dimensions of the human vagina as seen in three-dimensional vinyl polysiloxane casts. Gynecol Obstet Invest 42(3):178-182.
19. das Neves J, Palmeira-de-Oliveira R, Palmeira-de-Oliveira A, Rodrigues F, Sarmento B. in press. Current perspectives on vaginal drug delivery; Khutoryanskiy V, Ed., New Jersey: John Wiley & Sons.
20. Owen DH, Katz DF. 1999. A vaginal fluid simulant. Contraception 59(2):91-95.
21. Yoo JW, Acharya G, Lee CH. 2009. In vivo evaluation of vaginal films for mucosal delivery of nitric oxide. Biomaterials 30(23-24):3978-3985.
22. Garg S, Vermani K, Garg A, Anderson RA, Rencher WB, Zaneveld LJ. 2005. Development and characterization of bioadhesive vaginal films of sodium polystyrene sulfonate (PSS), a novel contraceptive antimicrobial agent. Pharm Res 22(4):584-595.
23. Woodley J. 2001. Bioadhesion: New possibilities for drug administration? Clin Pharmacokinet 40(2):77-84.
24. Neurath AR, Strick N, Li YY. 2003. Water dispersible microbicidal cellulose acetate phthalate film. BMC Infect Dis 3:27.
25. Valenta C. 2005. The use of mucoadhesive polymers in vaginal delivery. Adv Drug Deliv Rev 57(11):1692-1712.
26. Garg S, Goldman D, Krumme M, Rohan LC, Smoot S, Friend DR. 2010. Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets. Antiviral Res 88 Suppl 1:S19-S29.
27. Dobaria NB, Badhan AC, Mashru RC. 2009. A novel itraconazole bioadhesive film for vaginal delivery: Design, optimization, and physicodynamic characterization. AAPS PharmSciTech 10(3):951-959.
28. das Neves J, Amaral MH, Bahia MF. 2008. Vaginal drug delivery. In Pharmaceutical manufacturing handbook: Productions and processes; SC G, Ed. Hoboken, New Jersey: Wiley, pp 809-879.
29. Hani U, Bhat RS, Pasha MY. 2012. Formulation design and evaluation of bioadhesive: Vaginal films of metronidazole for vaginal candidiasis. Lat Am J Pharm 31(1):84-90.
30. Yoo JW, Dharmala K, Lee CH. 2006. The physicodynamic properties of mucoadhesive polymeric films developed as female controlled drug delivery system. Int J Pharm 309(1-2):139-145.
31. Garg S, Tambwekar KR, Vermani K, Kandarapu R, Garg A, Waller DP, Zaneveld LJ. 2003. Development pharmaceutics of microbicide formulations. Part II: Formulation, evaluation, and challenges. AIDS Patient Care STDS 17(8):377-399.
32. Garg S, Tambwekar KR, Vermani K, Garg A, Kaul CL, Zaneveld LJD. 2001. Compendium of pharmaceutical excipients for vaginal formulations. Pharm Techn Drug Deliv 25:14-24.
33. Rohan LC, Moncla BJ, Kunjara Na Ayudhya RP, Cost M, Huang Y, Gai F, Billitto N, Lynam JD, Pryke K, Graebing P, Hopkins N, Rooney JF, Friend D, Dezzutti CS. 2010. In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS ONE 5(2):e9310.
34. Dezzutti CS, James VN, Ramos A, Sullivan ST, Siddig A, Bush TJ, Grohskopf LA, Paxton L, Subbarao S, Hart CE. 2004. In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission. Antimicrob Agents Chemother 48(10):3834-3844.
35. Dobaria N, Mashru R. 2010. Design and in vitro evaluation of a novel bioadhesive vaginal drug delivery system for clindamycin phosphate. Pharm Dev Technol 15(4):405-414.
36. Smart JD. 2005. The basics and underlying mechanisms of mucoadhesion. Adv Drug Deliv Rev 57(11):1556-1568.
37. Rinehart M, Drake T, Robles F, Rohan L, Katz D, Wax A. 2012. Time-resolved microscopy for imaging refractive index distributions of dissolving microbicidal films. International Microbicides Conference, Sydney, Australia.
38. Technologies US. 2012. Thermostable probiotics for delivery with quick-dissolved polymeric films. International Microbicides Conference, Sydney, Australia.
39. Mauck CK, Baker JM, Barr SP, Johanson WM, Archer DF. 1997. A phase I comparative study of three contraceptive vaginal films containing nonoxynol-9. Postcoital testing and colposcopy. Contraception 56(2):97-102.
40. Mauck CK, Baker JM, Barr SP, Abercrombie TJ, Archer DF. 1997. A phase I comparative study of contraceptive vaginal films containing benzalkonium chloride and nonoxynol-9. Postcoital testing and colposcopy. Contraception 56(2):89-96.
41. WHO. 2001. WHO/CONRAD technical consultation on nonoxynol-9. Geneva: World Health Organization.
42. Ladipo OA, De Castro MP, Filho LC, Coutinho E, Waller DP, Cone F, Zaneveld LJ. 2000. A new vaginal antimicrobial contraceptive formulation: Phase I clinical pilot studies. Contraception 62(2):91-97.
43. Bunge K. 2012. Assessing the safety of dapivirine gel and film formulations. ClinicalTrialsgov identifier: NCT01548560. International Partnership for Microbicides, Inc. Available from URL: www.clinicaltrials.gov
44. Trifonova RT, Pasicznyk JM, Fichorova RN. 2006. Biocompability of solid dosage forms of anti-HIV 1 microbicides with the humam cervico-vaginal mucosa modeled ex vivo. Antimicrob Agents Chemother 50(12):4005-4010.
45. White BA, Creedon DJ, Nelson KE, Wilson BA. 2011. The vaginal microbiome in health and disease. Trends Endocrinol Metab 22(10):389-393.
46. Van Der Pol B. 2011. Diagnosing vaginal infections: It's time to join the 21st century. Curr Infect Dis Rep 12(3):225-230.
47. Esim Buyukbayrak E, Kars B, Karsidag AY, Karadeniz BI, Kaymaz O, Gencer S, Pirimoglu ZM, Unal O, Turan MC. 2010. Diagnosis of vulvovaginitis: Comparison of clinical and microbiological diagnosis. Arch Gynecol Obstet 282(5):515-519.
48. Repka MA, Repka SL, Mcginity JW. 2002. Patent US6375963.
49. Pauletti GM, Desai KJ, Roweton SL, Harrison DC, Sanders LM. 2007. Patent WO2004041118.
50. Leon T, Gable P. 2004. Patent WO2004103232.
51. Maniar M, Parandoosh S. 2005. Patent WO2005013906.
52. Wilson M, Desai KJ, Pauletti GM, Antoon MKJR, Clendening CE. 2006. Patent WO2006017341.
53. Jitian Y, Huiming G. 2008. Patent CN101199555.
54. Staab RJ. 2009. Patent US20090098188.
55. Liu X, Kresevic J. 2009. Patent US2009099149.
56. Coggins C, Elias CJ, Atisook R, Bassett MT, Ettiegnene-Traore V, Ghys PD, Jenkins-Woelk L, Thongkrajai E, VanDevanter NL. 1998. Women's preferences regarding the formulation of over-the-counter vaginal spermicides. AIDS 12(11):1389-1391.
57. Hardy E, Jimenez AL, de Padua KS, Zaneveld LJ. 1998. Women's preferences for vaginal antimicrobial contraceptives. III. Choice of a formulation, applicator, and packaging. Contraception 58(4):245-249.
58. Hillier S. 2011. Acceptability study of vaginal films for HIV prevention (FACE). ClinicalTrialsgov identifier: NCT01231763. University of Pittsburgh. Available from URL: www.clinicaltrials.gov.